Searchable abstracts of presentations at key conferences in endocrinology

ea0063p460 | Adrenal and Neuroendocrine Tumours 2 | ECE2019

Steroid hormones and cancer immunity - insights into adrenocortical carcinoma

Landwehr Laura-Sophie , Dexneit Thomas , Herterich Sabine , Sbiera Iuliu , Schreiner Jochen , Kroiss Matthias , Fassnacht Martin , Sbiera Silviu

Context: Adrenocortical carcinoma (ACC) are endocrine malignant neoplasms associated with severe aggressiveness. By applying of ‘multiple omics’ approach, we recently categorized ACC patients based on their steroidogenic activity and expression of immune activation marker, which is along with prognosis; an ‘immune’ phenotype with good and a ‘steroid’ phenotype with bad outcome.Hypothesis: Our central hypothesis focuses on th...

ea0049gp22 | Adrenal 3 | ECE2017

Epithelial to mesenchymal transition in adrenocortical tumours: focus on FGF-FGFR pathway and c-MET

Sbiera Iuliu , Altieri Barbara , Feuchtinger Annette , Hofner Kerstin , Walch Axel , Fassnacht Martin , Ronchi Cristina L , Kroiss Matthias , Sbiera Silviu

Ad Adrenocortical carcinoma (ACC) is an aggressive tumour and treatment remains unsatisfactory in advanced disease. Activation of epithelial to mesenchymal transition (EMT) is considered causative for metastatic spread in a variety of human cancers. Accordingly, new drugs were developed specifically targeting EMT with a focus on hepatocyte growth factor (HGF)/HGF receptor (c-MET) and fibroblast growth factor (FGF)/FGF receptor (FGFR) signalling.We here a...

ea0041oc2.3 | Receptors & Signalling | ECE2016

PRKACA mutations in adrenal Cushing impair association with the PKA regulatory subunit

Bathon Kerstin , Weigand Isabel , Ronchi Cristina L. , Di Dalmazi Guido , Beuschlein Felix , Sbiera Silviu , Fassnacht Martin , Calebiro Davide

In a previous study we found mutations in the main catalytic subunit of protein kinase A (PKA Cα) to be responsible for cortisol-secreting adrenocortical adenomas (ACAs). These mutations interfere with the formation of a stable holoenzyme, thus causing constitutive PKA activation. More recently, we identified additional mutations affecting PKA Cα in ACAs associated with overt Cushing syndrome: Ser213Arg_Leu212_Lys214insIle-Ile-Leu-Arg, Cys200_Gly201insVal, Trp197Arg,...

ea0037oc9.5 | Adrenal 2 | ECE2015

The Notch ligand Jagged1 is up-regulated in adrenocortical carcinomas and is associated with a favourable clinical outcome

Ronchi Cristina , Sbiera Silviu , Altieri Barbara , Steinhauer Sonja , Wild Vanessa , Bekteshi Michaela , Kroiss Matthias , Fassnacht Martin , Allolio Bruno

Background: Adrenocortical tumours consist of frequent adrenocortical adenomas (ACA) and highly malignant (ACC) with a still incompletely understood pathogenesis. Dysregulation of Notch signalling pathway is implicated in several cancers with oncogenic or tumour suppressor functions. Copy number gains and over-expression of Jagged1, a ligand of Notch receptor, was reported in ACC. The aim of the study was to evaluate the expression of Jagged1 and other Notch-r...

ea0070oc7.5 | Endocrine-related Cancer | ECE2020

Differential adrenal toxicity of SOAT1-inhibitors

Weigand Isabel , Sbiera Silviu , Kendl Sabine , Hanna Urlaub , Constanze Hantel , Katja Kiseljak-Vassiliades , Margaret E Wierman , Fassnacht Martin , Kroiss Matthias

Background: Mitotane is the only approved treatment for advanced adrenocortical carcinoma and was shown to inhibit Sterol-O-Acyl transferase 1 (SOAT1) which leads to the depletion of cholesterol esters and increase of free cholesterol in the ACC cell line H295R. Downstream activation of the endoplasmic reticulum stress (ER-stress) pathway results in decreased adrenocortical cell viability.Aim: To better characterize the effects of SOAT1 inhibition in ACC...

ea0070aep3 | Adrenal and Cardiovascular Endocrinology | ECE2020

Is there an epithelial to mesenchymal transition (EMT) in adrenocortical tumours?

Sbiera Iuliu , Kircher Stefan , Feuchtinger Annette , Höfner Kerstin , Karl Walch Axel , Fassnacht Martin , Kroiss Matthias , Sbiera Silviu

Introduction: Adrenocortical carcinoma (ACC) is an aggressive tumour with unsatisfactory treatment options in advanced disease. Activation of epithelial to mesenchymal transition (EMT) has been described as causative of metastatic spread in human cancers. New drugs were developed targeting EMT with a focus on FGF/FGFR signalling. We here asked whether EMT is relevant in ACC.Methods: We analysed 6 normal adrenal glands (NAG), 40 adrenocortical adenomas (A...

ea0070aep28 | Adrenal and Cardiovascular Endocrinology | ECE2020

The role of cytotoxic chemotherapy in adjuvant treatment of radically resected adrenocortical carcinoma

Kimpel Otilia , Shokry Daniel Bedrose Sara , Megerle Felix , Daher Marilyne , Kroiss Matthias , Amir Habra Mouhammed , Fassnacht Martin

Background: The recent ESE-ENSAT guidelines on adrenocortical carcinoma (ACC) indicated new treatment options for patients with “high risk for recurrence” as one of the major research topics for the field. However, since almost no data were available on the use of cytotoxic drugs in an adjuvant setting, no clear recommendation could be given. Here we report our experience with adjuvant platin-based therapy since 2002 at the University of Würzburg and MD Anders...

ea0070aep96 | Adrenal and Cardiovascular Endocrinology | ECE2020

Confirmatory testing of primary aldosteronism with saline infusion test and LC-MS/MS

Teresa Fuss Carmina , Brohm Katharina , Kurlbaum Max , Hannemann Anke , Kendl Sabine , Fassnacht Martin , Deutschbein Timo , Hahner Stefanie , Kroiss Matthias

Objective: The saline infusion test (SIT) is a standard confirmatory test for primary aldosteronism (PA) and based on impaired aldosterone suppression in PA compared to essential hypertension (EH). In the past, aldosterone was quantified using immunoassays (IA). Due to the more widespread use of liquid chromatography tandem mass spectrometry (LC-MS/MS) in clinical routine, we aimed at a method-specific aldosterone threshold for the diagnosis of PA during SIT and explored the d...

ea0070aep286 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

Liraglutide and PYY3–36 combination therapy partially achieves the metabolic benefits of Roux-en-Y gastric bypass surgery in diet-induced obese rats

Dischinger Ulrich , Hasinger Julia , Königsrainer Malina , Corteville Carolin , Otto Cristoph , Fassnacht Martin , Hankir Mohamed , Seyfried Florian

Background: Circulating levels of the appetite-suppressing and glucoregulatory gut hormones glucagon-like peptide 1 (GLP-1) and peptide tyrosine tyrosine 3–36 (PYY3–36) are markedly increased after Roux-en-Y gastric bypass surgery (RYGB), which may contribute to some of its profound metabolic benefits in morbidly obese individuals.Objectives: To directly compare the metabolic effects of chronic systemic administration of the clinic...

ea0070aep426 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

Effects of bariatric surgery in patients with craniopharyngioma

Dischinger Ulrich , Kötzner Laura , Koschker Ann-Cathrin , Haas Christina , Herrmann Martin , Fassnacht Martin , Seyfried Florian

Effects of Bariatric Surgery in Patients with CraniopharyngiomaObjectives: The prime objective of this study is the identification of the limiting factors of metabolic surgeries on weight reduction in patients with craniopharyngioma (CP) and consecutive hypothalamic obesity (HO).Patients: As of now, 37 patients were included, of which5 patients presented with HO and earlier bariatric surgery (mean BMI 50.44 kg/m2), ...